XML 55 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Description of Business, Basis of Presentation, and Operating Segment (Details)
12 Months Ended
Sep. 21, 2022
USD ($)
tranche
Dec. 31, 2022
USD ($)
segment
product
Dec. 31, 2021
USD ($)
Subsidiary, Sale of Stock [Line Items]      
Number of commercial asset products | product   1  
Number of late stage development drugs | product   1  
Cash, cash equivalents, and short-term investments   $ 75,096,000 $ 100,647,000
Amount drawn   $ 30,000,000  
Number of reportable segment | segment   1  
Number of operating segment | segment   1  
April 2019 ATM Agreement      
Subsidiary, Sale of Stock [Line Items]      
Remaining amount to be sold in the offering   $ 128,800,000  
Secured Debt | Term Loan Facility      
Subsidiary, Sale of Stock [Line Items]      
Debt instrument, term 5 years    
Aggregate principal amount $ 65,000,000 25,000,000  
Number of tranches | tranche 4    
Amount drawn   $ 30,000,000  
Secured Debt | Term B Loan      
Subsidiary, Sale of Stock [Line Items]      
Debt instrument undrawn amount $ 10,000,000